Jaka jest cena za Noxopharm Limited (NOX)

Cena za Noxopharm Limited (NOX) wynosi $0.04443294

Jaka jest kapitalizacja rynkowa dla Noxopharm Limited (NOX)

Kapitalizacja rynkowa dla Noxopharm Limited (NOX) wynosi $13.65M

Noxopharm Limited (NOX) Marża Operacyjna

Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.

Rok	Marża operacyjna	Zmień
2026 (TTM)	0.00%	-100.00%
2025	-342.14%	8.99%
2024	-313.92%	13.69%
2023	-276.12%	-1.43%
2022	-280.14%	7.54%
2021	-260.50%	31.83%
2020	-197.61%	-52.69%
2019	-417.69%	-63.54%
2018	-1,145.69%	-55.34%
2017	-2,565.11%	0.00%
2016	0.00%	0.00%

Rok

Marża operacyjna

Zmień

2026 (TTM)

0.00%

-100.00%

2025

-342.14%

8.99%

2024

-313.92%

13.69%

2023

-276.12%

-1.43%

2022

-280.14%

7.54%

2021

-260.50%

31.83%

2020

-197.61%

-52.69%

2019

-417.69%

-63.54%

2018

-1,145.69%

-55.34%

2017

-2,565.11%

0.00%

2016

0.00%

Firma	Marża operacyjna	Różnica w marży operacyjnej	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.57%	-	AU
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH

Firma

Marża operacyjna

Różnica w marży operacyjnej

Kraj